Antibe Therapeutics Inc.
ATBPF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | 0.14 | -0.02 | 0.12 |
| FCF Yield | -8.09% | -25.15% | -18.79% | -10.83% |
| EV / EBITDA | -8.60 | -4.28 | -2.91 | -7.59 |
| Quality | ||||
| ROIC | -8.58% | -9.50% | -10.06% | -5.28% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 1.28 | 0.79 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 40.22% | -40.31% | -35.54% | 6.47% |
| Safety | ||||
| Net Debt / EBITDA | 2.69 | 0.83 | 1.64 | 2.09 |
| Interest Coverage | -2,298.00 | -2,724.50 | -3,140.00 | -1,791.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |